Tenderwize
Retour à la recherche

Open-house rebate agreement for Dornase alfa

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Aug 03, 2027 · 339 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Dornase alfa (Desoxyribonuclease), ATC R05CB13

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

The notice explicitly says the contract documents must be submitted via the DTVP communication area and not via the off...

Contract conclusion is only possible until 03.08.2027, and monthly start dates depend on receipt of complete documents...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Sep 2027
  • Non-exclusive open-house rebate agreement for Dornase alfa (Desoxyribonuclease), ATC R05CB13.
  • Supply of pharmaceutical products under a predefined rebate contract.
Afficher le résumé complet

This is an open-house pharmaceutical supply arrangement by AOK Bayern for Dornase alfa (Desoxyribonuclease), ATC R05CB13, not a competitive award procedure in the usual sense. The model is non-exclusive and open to all pharmaceutical companies that meet the stated suitability requirement. No contract value is provided. Submission is possible electronically with a qualified electronic signature via DTVP or in paper form in duplicate originals. The deadline for contract conclusion is 03.08.2027, with monthly entry dates depending on when complete documents are received.

Risques

The notice explicitly says the contract documents must be submitted via the DTVP communication area and not via the off...

Contract conclusion is only possible until 03.08.2027, and monthly start dates depend on receipt of complete documents...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.
  • The signed contract and the completed annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be submitted.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreement for Dornase alfa

Open-house non-exclusive rebate agreement for the medicinal product Dornase alfa (Desoxyribonuclease), ATC R05CB13. The lot is for pharmaceutical products and is described as a supply arrangement. The notice states that the contract conditions are predefined and not individually negotiable. Source: structured data and notice text.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Sep 2025 - Sep 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Aug 03, 2027

Détails de la procédure

Date de publication
13 Aug 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
533448-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30